Metabolic Regulation
Compounds grouped here are studied for their activity across the pathways that regulate glucose and energy balance in preclinical models — incretin receptor agonism at GLP-1, GIP, and glucagon receptors, amylin and calcitonin receptor signaling, and NNMT inhibition of cellular methylation and NAD+ salvage. Common endpoints in the literature include receptor binding and selectivity, cAMP accumulation, gastric emptying rate, and hepatic lipid metabolism.
Retatrutide
10–30mg · COA published
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
- CAS
- 2381089-83-2
- MW
- 4731.32
- Purity
- Per published certificate
Semaglutide
5–20mg · COA published
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
- CAS
- 910463-68-2
- MW
- 4113.58
- Purity
- Per published certificate
Tirzepatide
10–30mg · COA published
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
- CAS
- 2023788-19-2
- MW
- 4813.45
- Purity
- Per published certificate
Cagrilintide
10mg · COA published
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
- CAS
- 1415456-99-3
- MW
- 4409
- Purity
- Per published certificate
5-Amino-1MQ
10mg · COA published
Small-molecule NNMT inhibitor studied for effects on cellular methylation capacity and NAD+ salvage.
- CAS
- 42464-96-0
- MW
- 159.21
- Purity
- Per published certificate
48
Certificates published
Published across 5 compoundsin this group, current and prior lots. Every certificate is issued by an independent laboratory and carries the issuing lab’s verification key, so each result can be checked with the laboratory directly.
Browse by research area
The same compounds, indexed by mechanism. Each area page lists everything in that category, not only the compounds studied for this goal.